Research and Development Expenses Breakdown: Amgen Inc. vs Soleno Therapeutics, Inc.

A Tale of Two Biotech Giants: Amgen Inc. vs Soleno Therapeutics, Inc.

In the ever-evolving world of biotechnology, research and development (R&D) expenses are a critical indicator of a company's commitment to innovation. Over the past decade, Amgen Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Amgen consistently allocated substantial resources, with expenses peaking at nearly $4.8 billion in 2021, reflecting a robust 35% increase from 2017. In contrast, Soleno's R&D spending, while significantly smaller, showed a remarkable growth trajectory, surging over 1,000% from 2014 to 2023. This stark difference highlights the diverse strategies within the biotech sector, where established giants like Amgen leverage their financial prowess, while emerging players like Soleno focus on rapid growth and innovation. As the industry continues to advance, these R&D investments will play a pivotal role in shaping the future of healthcare.